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The disintegration of the dystrophin–glycoprotein complex represents the initial pathobiochem-
ical insult in Duchenne muscular dystrophy. However, secondary changes in signalling, energy
metabolism and ion homeostasis are probably the main factors that eventually cause progressive
muscle wasting. Thus, for the proper evaluation of novel therapeutic approaches, it is essential to
analyse the reversal of both primary and secondary abnormalities in treated muscles. Antisense
oligomer-mediated exon skipping promises functional restoration of the primary deficiency in
dystrophin. In this study, an established phosphorodiamidate morpholino oligomer coupled to a
cell-penetrating peptide was employed for the specific removal of exon 23 in the mutated mouse
dystrophin gene transcript. Using DIGE analysis, we could show the reversal of secondary
pathobiochemical abnormalities in the dystrophic diaphragm following exon-23 skipping. In
analogy to the restoration of dystrophin, b-dystroglycan and neuronal nitric oxide synthase, the
muscular dystrophy-associated differential expression of calsequestrin, adenylate kinase, aldo-
lase, mitochondrial creatine kinase and cvHsp was reversed in treated muscle fibres. Hence, the
re-establishment of Dp427 coded by the transcript missing exon 23 has counter-acted dystrophic
alterations in Ca21-handling, nucleotide metabolism, bioenergetic pathways and cellular stress
response. This clearly establishes the exon-skipping approach as a realistic treatment strategy for
diminishing diverse downstream alterations in dystrophinopathy.
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1 Introduction
Duchenne muscular dystrophy (DMD) is a lethal genetic
disease of childhood that severely affects the integrity of
muscle fibres [1]. Dystrophinopathies are characterized by
primary abnormalities in the Dp427 isoform of the mem-
brane cytoskeletal protein dystrophin [2]. Severely pro-
gressive DMD and its more benign form, Becker muscular
dystrophy (BMD), represent allelic muscle disorders [1].
Various strategies for the therapy of dystrophinopathies
and related muscular disorders have been evaluated,
including biomedical interventions based on the down-
regulation of myostatin or utrophin substitution, pharma-
cological treatments, myoblast transfer, stem cell therapy
and gene transfer approaches [3–10]. None of these experi-
mental strategies have led to a long-lasting abrogation of
progressive muscle degeneration. In contrast, the recent
application of antisense oligomer-mediated exon skipping
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for treating muscular dystrophy has shown enormous
potential for the functional restoration of the primary defi-
ciency in dystrophin [11–13].
Removal of specific exons from the Dp427 transcript can
result in the production of internally shortened dystrophin
molecules [14]. In contrast to the amino- and carboxy-termi-
nal regions of full-length dystrophin with essential actin-
binding properties and dystroglycan interaction domains,
respectively, the central rod domain appears to be less critical
for the overall functional integrity of dystrophin [2]. Hence,
the exon skipping-mediated creation of shortened in-frame
transcripts, not unlike some BMD-associated forms of dys-
trophin, provides an ideal biomedical tool to overcome the
severely dystrophic DMD phenotype [15]. Systemic delivery
of a phosphorodiamidate morpholino oligomer (PMO) has
been clearly demonstrated to result in the body-wide expres-
sion of the dystrophin Dp427 isoform [16, 17]. In this study,
an established PMO coupled to a cell-penetrating peptide
was employed for the specific removal of exon 23 in the
mutated mouse dystrophin gene transcript, whose effective-
ness was previously demonstrated by PCR analysis, immu-
noblotting and immunofluorescence microscopy of dystro-
phin-positive fibres in exon-skippedmuscle [18]. We used the
established MDX model of DMD [19–21], because the non-
sense mutation in dystrophin exon 23 [22] triggers a severely
dystrophic phenotype in their diaphragm muscle [23].
Although it is well established that the molecular disin-
tegration of the dystrophin-associated glycoprotein complex
is a primary factor in rendering muscle fibres more suscep-
tible to necrosis [24–26], secondary alterations in signal
transduction, energy metabolism, ion homeostasis and exci-
tation-contraction coupling represent the critical secondary
events that finally lead to muscular dystrophy [27, 28].
Hence, when new therapeutic strategies for the reversal of
dystrophic symptoms are tested, it is crucial not only to
determine the effect on the primary deficiency, but also to
analyse the reversal of secondary abnormalities in experi-
mentally treated muscles. Previous MS-based proteomic
analyses of the dystrophic MDX animal model have shown
that a large cohort of proteins with a broad variety of cellular
functions show altered expression in dystrophin-deficient
fibres [29–33], suggesting a complex molecular pathogenesis
downstream of the primary genetic abnormality in dystro-
phin. The subproteomic study of Ca21-binding proteins in
dystrophic microsomes [31], the proteomic screening of the
dystrophic tibialis anterior muscle [29] and the DIGE survey
of the dystrophic diaphragm [33] have established a drasti-
cally altered density of essential marker proteins, including
the luminal Ca21-binding element calsequestrin, the meta-
bolic enzyme adenylate kinase and the muscle-specific stress
protein cvHsp, respectively, in MDX tissues [34].
Here, we show the reversal of these key secondary
pathobiochemical abnormalities in the expression profile of
markers of Ca21-homeostasis, nucleotide metabolism and
cellular stress response in PMO-treated MDX fibres. The
DIGE technique was employed since this method represents
one of the most advanced large-scale high-throughput tools
for the proteomic comparison of different sets of soluble
protein complements [35]. The reduction in gel-to-gel varia-
tions has greatly improved the biochemical evaluation of
trends in changed protein expression patterns [36–38] and
was therefore the preferred method here to detect altered
expression levels in previously established biomarkers of
dystrophinopathy [33]. The therapeutic restoration of dystro-
phin and its associated proteins b-dystroglycan and neuronal
nitric oxide synthase, as well as the reversal of the muscular
dystrophy-induced differential expression of calsequestrin,
adenylate kinase, aldolase, mitochondrial creatine kinase
and cvHsp in PMO-treated MDX muscle fibres, establishes
the exon skipping approach as a suitable biomedical strategy
for rectifying secondary abnormalities in X-linked muscular
dystrophy.
2 Materials and methods
2.1 Materials
CyDye DIGE fluor minimal dyes, the 2-D clean-up kit for
removal of contaminants prior to IEF, IPG strips of pH 3–10
(linear), IPG buffer of pH 3–10 for IEF, the 2D-Quant kit for
the determination of protein concentration in electrophoretic
samples, electrophoresis-grade chemicals, CBB protein dye
and ACN were obtained from Amersham Biosciences/GE
Healthcare (Little Chalfont, Bucks, UK). Sequencing grade-
modified trypsin for peptide generation was from Promega
(Madison, WI, USA), and a matrix kit containing CHCA and
the external peptide MS calibration kit Peptidemix-1 were
purchased from Laserbiolabs (Sophia-Antipolis, France).
Primary antibodies were obtained from Visionbiosystems
Novocastra, Newcastle upon Tyne, UK (mAb NCL-DYS2 to
the C-terminus of dystrophin isoform Dp427; mAb 8D5 to b-
dystroglycan), Abcam Cambridge, UK (pAb ab21128 to the
cardiovascular heat shock protein cvHSP; ab36329 to iso-
citrate dehydrogenase), Millipore, Bedford, MA, USA (pAb
07-571 to the neuronal nNOS isoform of nitric oxide syn-
thase), Affinity Bioreagents, Golden, CO, USA (mAb VIIID12
to the fast isoform of calsequestrin), Abnova, Heidelberg,
Germany (mAb A412-1A3 to the muscle-specific CA3-iso-
form of carbonic anhydrase) and Santa Cruz Biotechnology,
Santa Cruz, CA, USA (ab-sc28785 to adenylate kinase iso-
form AK1). Secondary antibodies used for immunoblot
analysis were obtained from Chemicon International
(Temecula, CA, USA). The Zenon Alexa Fluor 488 labelling
kit, SuperScript III reverse transcriptase and Trizol reagent
were from Invitrogen (Melbourne, Australia). AmpliTaq-
Gold DNA polymerase was obtained from Applied Biosys-
tems (Scoresby, Victoria, Australia). Chemiluminescence
substrates and protease inhibitors were from Pierce and
Warriner (Chester, UK) and Roche Diagnostics (Mannheim,
Germany), respectively. Immobilon-NC membranes and C-
18 Zip-Tips for desalting were purchased from Millipore.
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The presiliconization medium Sigmacote, ultrapure lysine
for quenching the DIGE labelling reaction and DNase-I en-
zyme, as well as all other analytical-grade chemicals were
obtained from Sigma Chemical Company (Dorset, UK).
2.2 MDX animal model
An established animal model of DMD is represented by the
MDX mouse, which is missing the Dp427 isoform of dys-
trophin due to a point mutation [22]. Although limb muscles
do not exhibit severe fibre degradation [19], the MDX dia-
phragm is severely dystrophic [23] and was therefore ana-
lysed in this study. C57BL/10ScSnmdx inbred mice were pur-
chased from the Animal Resource Centre, Perth and housed
at the Animal Care Unit, University of Western Australia,
Perth. Animals were kept under standard conditions and all
procedures were performed in accordance with the National
Health andMedical Research Council of Australia guidelines
on the use of animals for scientific experiments, and were
approved by the Animal Ethics Committee of the University
of Western Australia (approval number 03/100/373).
2.3 Antisense oligomer treatment
The PMO probe PMO-P007 was re-suspended in sterile, pu-
rified water at a concentration of 5 mM and stored at 47C
until required [17]. PMO-P007 was diluted in normal saline
and warmed to 377C for 5 min before being delivered to the
mice by the intraperitoneal route, at a dosage of 10 mg/kg per
week, beginning at 3 days of age [18]. The improved design
of antisense oligonucleotides, the optimization of their
delivery and control experiments have previously been
described in detail [11, 14, 16–18]. Sham treated animals
were injected with an equivalent volume of normal saline.
Mice were weighed weekly to monitor for any effects of the
treatment on growth of pups or stable weight in the adults.
At 10 wk of age the mice were anaesthetized (sodium pento-
barbitone 40 mg/kg) and then euthanized by cervical dis-
location. Tissues were dissected and frozen in isopentane
cooled by liquid nitrogen. For analysis, frozen samples were
transported on dry ice to Dublin and stored at2807C prior to
sample preparation.
2.4 RNA preparation and RT-PCR analysis
To establish successful exon skipping, PCR analysis of the
dystrophin transcript from normal, mdx and PMO-treated
samples was performed. RNA was isolated from frozen tis-
sue blocks using Trizol reagent (Invitrogen) according to the
manufacturer’s protocol. RT-PCR was performed on 100 ng
of total RNA for 35 cycles of amplification, using 1 U of
SuperScript III in a 12.5 mL reaction. Primers amplifying
exons 18–26 [16–18] were used at 947C for 30 s, 557C
annealing for 1 min and 687C extension for 2 min. One
microlitre of the RT-PCR product was used for secondary
amplification with 6 min hot start and 30 cycles at 557C
using AmpliTaq-Gold DNA polymerase according to manu-
facturer’s instructions (Applied Biosystems). Products were
fractionated on 2% agarose gels, stained with ethidium bro-
mide and the images captured by a Chemi-Smart 3000 gel
documentation system (Vilber Lourmat, Marne La Vallee,
France).
2.5 Sample preparation
DIGE analysis was performed with two experimental
designs, one with three and the other one with two different
biological samples, represented by normal versusMDX versus
MDX-PMO, and MDX versus MDX-PMO, respectively. The
analysis of crude skeletal muscle preparations by DIGE
technology has previously been optimized by our laboratory
[33, 39, 40]. For the combined proteomic profiling of all three
specimens, 12 individual biological replicates of muscle
samples (four Control, four MDX and four PMO), and for
the direct comparison of MDX versus treated specimens,
eight individual muscle samples (four MDX, four MDX-
PMO) were quick-frozen in liquid nitrogen and ground up
into a fine powder using a pestle and mortar. Fractions were
added to lysis buffer (9.5 M Urea, 4% w/v CHAPS, 30 mM
Tris-Cl, pH 8.5, 2% ampholytes pH 3–10 and 100 mM DTT).
In order to eliminate excessive viscosity due to the presence
of DNA, 2 mL of DNase-I (200 U) were added per 100 mL of
extraction buffer [33]. The suspension was also supple-
mented with a protease inhibitor cocktail (0.2 mM pefabloc,
1.4 mM pepstatin, 0.15 mM aprotinin, 0.3 mM E-64, 1 mM leu-
petin, 0.5 mM soybean trypsin inhibitor, 1 mM EDTA) to
avoid proteolytic degradation of muscle proteins, and then
incubated for 3 h at room temperature, with gentle vortexing
every 10 min for 30 s [40]. The samples were briefly soni-
cated, on ice, and spun at 20 0006g for 20 min. The protein-
containing middle layer was carefully removed and, prior to
dye labelling, samples were treated with the 2-D clean-up kit
from GE Healthcare and then resuspended in DIGE com-
patible lysis buffer (9.5 M Urea, 4% w/v Chaps, 30 mM Tris-
Cl, pH 8.5). Protein concentration was determined using the
2-D quant kit fromGEHealthcare. The pH value was verified
and, if needed, was adjusted to pH 8.5.
2.6 DIGE labelling
Samples were labelled with N-hydroxy succinimidyl ester
derivatives of the cyanine dyes Cy2, Cy3 and Cy5 following a
standard protocol [38]. Typically, 50 mg of lysate was mini-
mally labelled with 200 pmol of either Cy3 or Cy5 for com-
parison on the same 2-D gel [33, 40]. Labelling reactions were
performed on ice in the dark for 30 min and then quenched
with a 50-fold molar excess of free lysine to dye for 10 min on
ice. A pool of all samples was also prepared and labelled with
Cy2 to be used as a standard on all gels to aid image match-
ing and crossgel statistical analysis. Typically, 4.17 mg of C1-
C4, MDX1-MDX4 and PMO1-PMO4 were labelled with Cy2.
To conform to best experimental practice, a randomized
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labelling was performed. Four biological replicates from each
of the three experimental populations were either labelled
with Cy3 or Cy5 minimal dyes. Samples were both evenly
distributed between CyDye Fluors and between analytical
gels. The labelled protein extracts were pooled and immedi-
ately used for electrophoresis. An equal volume of 26sam-
ple buffer (9.5 M Urea, 4% w/v CHAPS, 2% IPG buffer
pH 3–10 and 130 mM DTT) was added and this suspension
was left on ice for 10 min prior to electrophoretic separation.
For the direct comparison of MDX versus MDX-PMO sam-
ples, the above protocol was adapted accordingly. As descri-
bed above, 50 mg of lysate were minimally labelled with
200 pmol of either Cy3 or Cy5 for comparison on the same 2-
D gel, and for the pooled standard, typically 6.25 mg of
MDX1-MDX4 and PMO1-PMO4 were labelled with Cy2.
2.7 Gel electrophoresis
The 2-D gel electrophoretic separation of fluorescently label-
led muscle proteins was carried out by standard procedure
using the recommended total protein concentration of
150 mg protein per comparative DIGE gel [39]. Using a
reswelling tray from GE Healthcare, IPG strips pH 3–10
(linear) were rehydrated for 12 h with 0.45 mL of rehydration
buffer (9.5 M urea, 4% w/v CHAPS, 100 mM DTT, 2%
ampholytes pH 3–10), which had been complemented with
0.05% bromophenol blue as a tracking dye. Following place-
ment of the first-dimension strips gel-side up into the Ettan
IPGphor manifold and coverage with 108 mL of dry strip
cover fluid, protein samples were loaded by anodic cup load-
ing and were then run on the IPGphor III IEF system from
GE Healthcare. The following IEF gel running conditions
were used: 180 min at 300 V (step-and-hold), 180 min at
600 V (gradient), 180 min at 1000 V (gradient), 180 min at
8000 V (gradient), 240 min at 8000 V (step-and-hold),
180 min at 500 V (step-and-hold) and 120 min at 8000 V
(step-and hold). Following IEF strips were equilibrated for
15 min in equilibration buffer (6 M Urea, 30% w/v glycerol,
2% w/v SDS, 100 mM Tris-Cl, pH 8.8) containing 100 mM
DTT and another 15 min in equilibration buffer supple-
mented with 0.25 M iodoacetamide. Using the Ettan DALT
twelve system from GE Healthcare, the second dimensional
separation of muscle proteins was performed with 12.5% re-
solving gels. Following brief washing in SDS running buffer,
IEF strips were positioned on top of the second-dimension
slab gel with the help of a 1% w/v agarose sealing gel, poured
on top of the strip and left to solidify. Six DIGE gels and two
pick gels were run for 0.2 W/gel for 1 h, followed by 0.4 W/
gel for 1 h and then ran at 1.5 W/gel overnight until the blue
dye front had just disappeared from the bottom of the gel.
2.8 Gel image acquisition and image analysis
Fluorescently labelled proteins were visualized using the
Typhoon Trio variable mode imager system from Amersham
Biosciences/GE Healthcare. Cy2, Cy3 and Cy5 images were
scanned using a 488, 532 and 633 nm laser, respectively. The
PMT value for all scanned images was between 500 and
600 V. All gels were scanned at 100 mm resolution and, prior
to analysis, gel images were cropped using the ImageQuant
TL software program [40]. Gel analysis was performed with
the DeCyder V6.5 2-D analysis software package for DIGE
(Amersham Biosciences/GE Healthcare). The DeCyder dif-
ferential in-gel analysis module was used for pairwise com-
parison of each set of differential samples to the pooled
standard present in each gel and for the calculation of nor-
malized spot volume/protein abundance. The 18-spot maps
corresponding to the six gels were used to calculate average
abundance and paired Student’s t-test p-values for each pro-
tein across all analytical gels. This was carried out with the
DeCyder biological variation analysis module taking into
account Cy3/Cy2 and Cy5/Cy2 ratios for each individual
protein. Protein spots that showed a significant increase or
decrease were then identified using MS fingerprinting anal-
ysis.
2.9 Sample preparation for MS analysis
2-D muscle protein spots of interest, electrophoretically
separated on Coomassie-stained pick gels parallel to DIGE
gels, were washed, digested and identified by MALDI-TOF
MS analysis as previously optimized by our laboratory [33,
39, 40]. The gel was first washed with deionized water (two
changes, 10 min each). CBB-stained spots of interest were
excised from the gels, using a blue pipette tip with the top cut
off and placed into a presilconized (Sigma, Sigmacote)
1.5 mL Eppendorf tubes. The gel plugs were then destained,
desalted and washed as follows: gel plugs were first washed
with water and 50 mM NH4HCO3/ACN 1:1 v/v for 15 min.
All remaining liquid was removed, and enough ACN was
added to cover the gel plugs. ACN was removed and gel plugs
were rehydrated in 50 mM NH4HCO3. After 5 min, an equal
volume of ACN was added. Following 15 min of incubation,
all the liquid was removed and the gel plugs were then
shrunk in ACN. The ACN was removed and gel plugs were
dried down for 30 min using a Heto type vacuum centrifuge
from Jouan Nordic A/S (Allerod, Denmark). Individual gel
plugs were rehydrated in digestion buffer (1 mg of trypsin in
20 mL of 50 mM NH4HCO3) to cover the gel plugs. More
digestion buffer was added if all the initial volume had been
absorbed by the gel pieces. The samples were incubated at
377C for 1 h. The excess enzyme solution was removed and
8 mL of 50 mMNH4HCO3 was added to each plug to keep the
gel plugs wet and the samples were then incubated at 377C
overnight. After digestion, the samples were centrifuged at
12 0006g for 10 min. The supernatant was carefully
removed from each sample and placed into clean and
silconized plastic tubes. The resulting peptides were extrac-
ted by three sequential extraction steps each of 30 min dura-
tion and a volume of 40 mL each. The solvent of the first
extraction consisted of 50% ACN/0.1% TFA. Extraction was
aided by sonication in a Branson 3100 water bath for 30 min.
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Samples were then briefly spun down. The solvents for the
remaining two extractions were 60% ACN/0.1% TFA and
80% ACN/1% TFA. The combined extracts were con-
centrated in a vacuum centrifuge and peptides resuspended
in 8 mL of 3% TFA. Samples were stored at 2707C until ana-
lysed by MS methodology.
2.10 MALDI-TOF MS analysis
MALDI-TOF tryptic PMF of in-gel digests from normal, dys-
trophic andPMO-treatedmuscle protein specieswas conducted
by standardmethodology [40]. Tryptic peptides from individual
samplesweredesaltedusingMilliporeC-18Zip-Tips and eluted
onto the sample plate with the matrix solution (5 mg/mL
CHCA in 50% v/v ACN/0.1% v/v TFA). Mass spectra were
recorded using an Ettan MALDI-TOF Pro-instrument from
AmershamBiosciences operating in the positive reflectormode
at the following parameters: accelerating voltage 20 kV; and
pulsed extraction: on (focus mass 2500). Standard peaks of
angiotensin III (897.5 m/z) and ACTH (2465.19 m/z) were
used for internal calibration. MALDI evaluation software was
used for the analysis of mass spectra and protein identification
was achievedwith thePMFProFoundsearch engine for peptide
mass fingerprints. All certainty hits of diaphragm muscle pro-
teins generated by the ProFound search engine were matched
against the publicly available search engine MASCOT (http://
www.matrixscience.com).
2.11 Immunoblotting
In order to confirm altered expression levels of distinct dia-
phragm muscle proteins, as revealed by fluorescence DIGE
analysis, 2-D immunoblotting with highly specific primary
antibodies was employed [33, 40]. The soluble muscle pro-
teome was electrophoretically separated as described above
and then transferred at 100 V for 80 min to Immobilin NC-
pure membranes using a Transblot Cell from BioRad
Laboratories (Hemel Hempstead, Herts, UK). 2-D blots were
blocked in 50 mM sodium phosphate, pH 7.4, 0.9% w/v
NaCl, containing 5% w/v fat-free milk powder, followed by
exposure to sufficiently diluted primary antibodies, extensive
washing, incubation with peroxidase-conjugated secondary
antibodies and finally washed again prior to visualization of
immunodecorated muscle protein spots. The SuperSignal
ECL kit from Pierce and Warriner was used for evaluating
antibody labelling intensity and a Typhoon Trio variable
mode imager from Amersham Biosciences/GE Healthcare
with ImageQuant TL software was used for image acquisi-
tion.
2.12 Immunofluorescence microscopy
Microscopical localization of diaphragm proteins was car-
ried out as previously described in detail [18]. Dystrophin,
b-dystroglycan and the neuronal nNOS isoform of nitric
oxide synthase were detected by antibody labelling in 6 mm
unfixed transverse cryosections. Immunofluorescence
labelling was performed using the Zenon Alexa Fluor 488
labelling kit according to the protocol recommended by the
manufacturer, but omitting the initial fixation step. Dia-
phragm sections were viewed with an Olympus IX-70
inverted microscope and the images captured on an
Olympus DP-70 digital camera. Images in each montage
were photographed using the same parameters to allow
comparison.
3 Results
3.1 Proteomic profiling of antisense-induced exon
skipping in dystrophic diaphragm
In order to demonstrate that exposure to PMO resulted in
the specific removal of exon 23 in the mutated mouse
dystrophin gene transcript, the PCR analysis of transcripts
from RNA prepared from normal, MDX and PMO-treated
mice is shown in Fig. 1A. The full-length transcript is
represented by a 1357 bp product and the exon-23 deleted
transcript by a 1144 bp product. Following the establish-
ment of successful exon skipping, which has previously
been described in detail by Wilton and coworkers [16–18],
immunofluorescence microscopy was used to show the
relocation of dystrophin in PMO-treated diaphragm pre-
parations. As illustrated in Fig. 1B, antibody labelling of
dystrophin and two of its associated elements, b-dystrogly-
can and the neuronal nNOS isoform of nitric oxide syn-
thase, showed the surface localization of these proteins in
PMO-treated tissue. Since this also agreed with successful
exon skipping and established the restoration of essential
components of the dystrophin-associated sarcolemma
complex, the same diaphragm specimens were used for a
subsequent proteomic profiling analysis. Differential label-
ling with the fluorescent dyes Cy2, Cy3 and Cy5 was car-
ried out with a combination of four biological repeats of
normal, MDX and PMO-treated MDX specimens. Figure 2
illustrates the composition of a representative set of six
analytical DIGE gels. In our study, we conformed to best
experimental practice using the DIGE technique, as
reviewed by Friedman and Lilley [41]. A randomized label-
ling protocol was followed and samples were evenly dis-
tributed with respect to CyDye fluor staining and the
cohort of analytical gels [35–38]. DIGE analysis of experi-
mental exon-skipping therapy was carried out with two
experimental designs. As shown in Figs. 3 and 4, the first
approach was performed with three different biological
samples, representing normal versus MDX versus MDX-
PMO specimens. In contrast, the second analytical
approach focused on two different biological samples,
representing MDX versus MDX-PMO specimens (Figs. 5
and 6). Subsequently, proteomic findings were validated by
comparative immunoblot analysis of key muscle marker
proteins, as shown in Fig. 7.
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Figure 1. PCR and immuno-
fluorescence analysis of dystro-
phin in antisense oligomer-trea-
ted MDX diaphragm. (A) RT-PCR
analysis of normal, MDX and
PMO-treated diaphragm tissue.
The product of 1357 bp repre-
sents the full-length dystrophin
transcript, whereas the products
of 1144 and 998 bp represent
transcripts excluding exon 23,
and exons 22 and 23, respec-
tively. PMO-1 to PMO-5 repre-
sents preparations from five in-
dividual MDX mice treated with
antisense oligonucleotides. The
outer lanes contain a 100 bp
ladder. (B) The restoration of
surface expression of dystro-
phin, b-dystroglycan and the
neuronal nNOS isoform of nitric
oxide synthase in PMO-treated
MDX tissue as compared to
untreated MDX diaphragm
muscle. Immunofluorescence
microscopy was performed with
6 mm unfixed cryosections. Bar
equals 50 mm.
3.2 Reversal of pathobiochemical abnormalities in
dystrophic diaphragm
The proteomic comparison of normal versus MDX versus
PMO-treated MDX specimens is illustrated in the Cy2-label-
led DIGE master gel in Fig. 3. Out of approximately 2500
detectable 2-D protein spots, 20 muscle proteins showed a
differential expression pattern. The comparative gel electro-
phoretic analysis of the normal versus the MDX diaphragm
proteome, employing a Typhoon Trio variable imager and
DeCyder 2-D analysis software, showed five increased and 15
decreased protein species. The overall 2-D spot pattern of the
master gel agrees with our previously published studies on
the dystrophic diaphragm muscle [32–34]. Muscle protein
species with a changed abundance in MDX diaphragm,
ranging in molecular mass from 6.2 kDa (a-globin) to
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Figure 2. Overview of DIGE analysis of antisense
oligonucleotide-induced exon skipping in dys-
trophic MDX diaphragm. (A–F) The composition
of a set of six analytical DIGE gels. To conform to
best experimental practice, a randomized label-
ling protocol was performed. Four sample repli-
cates from each of the three experimental popu-
lations (NOR, normal diaphragm; MDX; dys-
trophic diaphragm; PMO, PMO-treated
dystrophic diaphragm) were either labelled with
Cy3 or Cy5 minimal dyes. Samples were both
evenly distributed between CyDye Fluors and
between analytical gels. A pool of all samples
was prepared and labelled with Cy2 to be used
as a standard on all gels to aid image matching
and crossgel statistical analysis.
72.6 kDa (succinate dehydrogenase), covered a pI range from
pI 5.0 (myosin light chain) to pI 9.2 (isocitrate dehy-
drogenase). Table 1 lists the identification of the majority of
these proteinsusingMALDI-TOFMS tryptic PMFfrom in-gel
digests. Diaphragm muscle components with a disturbed
expression pattern belonged to the class of cellular compo-
nents that are involved in muscle contraction, cytoskeleton
formation, mitochondrial function, metabolism, ion home-
ostasis, and chaperone function. In Fig. 4 are shownexpanded
views of DIGE gels of the fluorescently labelled normal mus-
cle proteome, the dystrophic protein complement, PMO-
treated specimens and pooled standards, as well as the com-
parative graphic representation of spots representing indi-
vidual marker proteins. Most importantly, the AK1 iso-
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Figure 3. Two-dimensional gel electro-
phoretic analysis of dystrophic dia-
phragm following PMO-induced exon
skipping. A Cy2-labelled master gel of
the total soluble protein complement
from normal diaphragm versus dys-
trophic diaphragm versus PMO-treated
dystrophic diaphragm muscle is shown.
Muscle proteins with a differential
expression level are marked by circles
and are numbered 1–20. See Table 1 for a
detailed listing of skeletal muscle pro-
teins with a changed abundance in dys-
trophic or treated fibres. The pH values
of the first dimension gel system and
molecular mass standards (in kDa) of the
second dimension are indicated on the
top and on the left of the panels, respec-
tively.
form of adenylate kinase was confirmed to be reduced in
dystrophic fibres as previously reported by Ge et al. [29],
but this altered expression profile was reversed by PMO-
mediated exon skipping. The reduced expression of aldo-
lase and isocitrate dehydrogenase was also partially
reversed by PMO application suggesting therapeutic
changes in key metabolic steps of glycolysis and the citric
acid cycle. In contrast to the reduction in many metabolic
enzymes, muscular dystrophy causes a profound upreg-
ulation of small stress proteins, such as the muscle-spe-
cific heat shock protein cvHsp [33]. The DIGE analysis of
this heat shock protein presented in Fig. 3 indicates a
less intense stress response in treated MDX fibres.
3.3 Proteomic comparison of MDX versus
PMO-treated MDX preparations
The direct comparison of MDX versus PMO-treated MDX
preparation revealed a cohort of 15 protein species with a
differential expression pattern. Figure 5A shows a repre-
sentative master gel of the total soluble protein comple-
ment from MDX muscle versus PMO-treated dystrophic
diaphragm. 2-D gel images with a Cy2-labelled pooled
standard, Cy3-labelled dystrophic MDX preparations and
Cy5-labelled PMO-treated dystrophic samples are presented
in Figs. 5B–D, respectively. Table 2 lists the identification
of the majority of these proteins using MALDI-TOF MS
tryptic PMF from in-gel digests. In analogy to the above
outlined results obtained by the comparison of three bio-
logical samples, this analytical approach revealed that
muscle proteins with an altered expression level belonged
to the class of cellular components that are involved in
cytoskeletal activity, glycolysis, mitochondrial function,
metabolic transportation steps, Ca21-homeostasis and
chaperone function. Expanded views of DIGE gels of the
fluorescently labelled dystrophic protein complement versus
PMO-treated specimens, as well as the comparative gra-
phic representation of spots representing individual mark-
er proteins, are shown in Fig. 6. An important finding is
the changed abundance of cvHsp. Direct comparison of
this relatively minor muscle protein in MDX versus PMO-
treated dystrophic specimens showed a drastic decline in
cvHsp density following exon skipping. Hence, the pre-
viously reported enhanced cellular stress response and
higher cvHsp-related chaperone function in the dystrophic
phenotype [33, 42] is being lowered in PMO-treated fibres.
In addition, our DIGE-based survey demonstrated that the
altered expression profile of adenylate kinase isoform AK1
and the mitochondrial isozyme of creatine kinase in dys-
trophic fibres were partially reversed by PMO-mediated
exon skipping (Fig. 6). Hence, the proteomic data pre-
sented here suggest that the modified expression of estab-
lished markers of secondary dystrophic changes in nucleo-
tide metabolism have been reversed by exon-skipping ther-
apy.
3.4 Immunoblotting confirms exon skipping-induced
reversal of dystrophic abnormalities
Verification of proteomic data was carried out by 2-D
immunoblot analysis. Dystrophin does not exist in isola-
tion at the muscle surface membrane, but is tightly
associated with numerous sarcolemmal proteins, e.g. sar-
coglycans, dystroglycans, dystrobrevin, syntrophins and
sarcospan [43]. Deficiency of the Dp427 isoform results
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Figure 4. Biochemical status of
muscular dystrophy-associated
markers in antisense oligomer-
treated MDX diaphragm.
Expanded views of 2-D gels of
the CyDye-labelled samples
from normal diaphragm versus
dystrophic MDX diaphragm ver-
sus PMO-treated dystrophic dia-
phragm muscle (MDX-PMO), as
well as the comparative graphic
representation of protein spots
representing adenylate kinase
(AK), isocitrate dehydrogenase
(ICDH), aldolase (ALD), and the
small heat shock protein cvHsp
are shown.
in the drastic reduction in most dystrophin-associated
proteins [44, 45], it was therefore of interest to determine
the effect of exon skipping on the expression of a key
element of the dystrophin–glycoprotein complex. As il-
lustrated in Fig. 7, the abundance of b-dystroglycan was
drastically elevated following exposure to PMO. Rescued
b-dystroglycan expression established that the initial
downstream abnormality in dystrophin deficiency is
partly rectified in PMO-treated diaphragm. This agrees
with the immunofluorescence analysis shown above in
Fig. 1B. Re-establishment of dystrophin is clearly asso-
ciated with the reappearance of b-dystroglycan and nNOS
in the cellular periphery of PMO-treated MDX fibres.
Since most peripheral or integral membrane-associated
muscle proteins cannot be properly assessed by DIGE
methodology, immunoblotting of the Ca21-binding pro-
tein calsequestrin was carried out. A severe reduction in
this luminal sarcoplasmic reticulum protein has pre-
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Figure 5. 2-D gel electrophoretic analy-
sis of dystrophic versus PMO-treated
diaphragm. (A) A Cy2-labelled master
gel of the total soluble protein comple-
ment from dystrophic diaphragm versus
PMO-treated dystrophic diaphragm
muscle. Muscle proteins with a differ-
ential expression level are marked by
circles and are numbered 1–15. See
Table 2 for a detailed listing of skeletal
muscle proteins with a changed abun-
dance in dystrophic or treated fibres.
The pH values of the first dimension gel
system and molecular mass standards
(in kDa) of the second dimension are
indicated on the top and on the left of the
panels, respectively. (B)–(D) shows
representative images of 2-D gels with
Cy2-labelled pooled standard, Cy3-
labelled dystrophic MDX preparations
and Cy5-labelled PMO-treated dys-
trophic samples (MDX-PMO), respec-
tively.
viously been linked to muscular dystrophy [31]. As shown in
Fig. 7, exon skipping appears to restore the expression of this
essential ion-handling protein. This suggests that PMO-
treatment may at least partially abolish the Ca21-induced
secondary abnormalities in muscular dystrophy. In addition,
the immunoblotting of cvHsp, carbonic anhydrase, adeny-
late kinase and isocitrate dehydrogenase confirmed the find-
ings of the DIGE analysis. The exon-skipping approach
appears to reverse abnormal expression levels in a wide
range of diaphragm proteins.
4 Discussion
Although the disintegration of the dystrophin-mediated
linkage between the extracellular matrix component
laminin and the subsarcolemmal actin cytoskeleton is
considered the most crucial initial factor in X-linked
muscular dystrophy [24], the secondary events rendering
a muscle fibre more susceptible to necrosis are not well
understood. Recent proteomic surveys have demonstrated
that the primary deficiency in the full-length Dp427 iso-
form of dystrophin and the concomitant loss in dystro-
phin-associated proteins cause a severely disturbed pro-
tein expression pattern in dystrophic muscle fibres [29–
33]. The primary molecular collapse of the membrane
cytoskeleton seems to trigger altered expression levels for
a great variety of muscle proteins involved in diverse cel-
lular functions [34], making the study of the molecular
pathogenesis of dystrophinopathy a difficult task. This
pathological aspect of muscular dystrophy was clearly
confirmed by the analytical findings of this investigation.
Changed diaphragm proteins, as identified by DIGE
analysis, can be grouped as muscle components involved
in chaperone activity (cvHsp, chaperonine Hsp1, aB
crystalline), cytoskeletal function (vimentin, desmin,
myotilin), nucleotide metabolism (adenylate kinase, crea-
tine kinase), muscle contraction (myosin light chains),
glycolysis (aldolase, triosephosphate isomerase), the citric
acid cycle (isocitrate dehydrogenase, succinate dehy-
drogenase), aldehyde metabolism (aldehyde dehy-
drogenase), oxygen transport (myoglobin, b-haemoglobin,
a-globin), the remethylation pathway of homocysteine
homeostasis (betaine-homocysteine methyltransferase),
the polyol pathway of glucose metabolism (sorbitol dehy-
drogenase), cytosolic calcium homeostasis (regucalcin),
and the regulation of acid–base balance (carbonic anhy-
drase).
The proteomic profiling of experimental exon skip-
ping suggests that many of these secondary alterations
can be reversed in the MDX animal model. Both, the
muscular dystrophy-associated loss of certain metabolic
regulators and the compensatory upregulation of chaper-
ones and enzymes can be, at least partially, counter-acted
by the specific removal of exon 23 in the mutated mouse
dystrophin gene transcript [18]. Previous biochemical
studies and more recent proteomic investigations have
established an altered status of distinct nondystrophin-
related muscle proteins as an integral part of the bio-
marker signature of X-linked muscular dystrophy [29,
33], besides the primary deficiency in dystrophin and
secondary reduction in dystroglycans, sarcoglycans, dys-
trobrevins, syntrophins and sarcospan [24–26]. For exam-
ple, pathobiochemical indicators of dystrophinopathy are
represented by adenylate kinase, calsequestrin and cvHsp
[34]. The determination of their expression levels indi-
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Figure 6. Proteomic profiling of
dystrophic versus antisense oli-
gomer-treated MDX diaphragm.
Expanded views of 2-D gels of
the CyDye-labelled samples
from dystrophic MDX dia-
phragm versus PMO-treated
dystrophic diaphragm muscle
(MDX-PMO), as well as the
comparative graphic repre-
sentation of protein spots repre-
senting the small heat shock
protein cvHsp, adenylate kinase
(AK) and the mitochondrial
creatine kinase (mCK) are
shown.
cates a reversal of secondary dystrophic symptoms fol-
lowing PMO-treatment. A lower density of the AK1 iso-
form of adenylate kinase was previously observed in both
dystrophic limb [29] and diaphragm [33] muscle, trigger-
ing a diminished enzyme activity in MDX fibres. The
reversal of this decreased enzyme density by exon skip-
ping therapy is an excellent result showing that this
novel approach may be useful for successfully treating
some of the dystrophin-associated abnormalities in
nucleotide metabolism. In normal fibres, creatine kinase
and adenylate kinase provide a major nucleotide pathway
[46]. Hence, altered expression levels within this enzyme
system may trigger severe disturbances in nucleotide
ratios in dystrophin-deficient fibres. Exposure to ther-
apeutic PMO probes appears to rectify this major meta-
bolic defect in muscular dystrophy.
The calcium hypothesis of dystrophinopathy proposes
that a causal connection exists between the loss of sarco-
lemmal integrity and Ca21-dependent proteolysis of muscle
proteins [47–49]. Abnormal ion handling in mechanically
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Figure 7. 2-D immunoblot anal-
ysis of muscular dystrophy-
associated markers in antisense
oligomer-treated MDX dia-
phragm. An expanded view of
immunodecorated 2-D spots
representing the dystrophin-
associated surface glycoprotein
b-dystroglycan (b-DG), the sar-
coplasmic reticulum Ca21-bind-
ing protein calsequestrin (CSQ),
the small heat shock protein
cvHsp, carbonic anhydrase iso-
form CA3, adenylate kinase iso-
form AK1 and isocitrate dehy-
drogenase (ICDH) in normal dia-
phragm versus dystrophic MDX
diaphragm versus PMO-treated
dystrophic diaphragm muscle
(MDX-PMO) is shown. The posi-
tion of immuno-decorated spots
is marked by arrowheads.
stressed fibres eventually leads to skeletalmuscleweakness [50].
Deficiency in dystrophin is clearly associated with the reduced
expression of several Ca21-binding and Ca21-shuttle proteins
[31, 51, 52]. As shown in this study, exon skipping partially
restores the expression of calsequestrin in the dystrophic sarco-
plasmic reticulum. Consequently, PMO-treatment appears to
abolish, at least partially, Ca21-level associated abnormalities in
muscular dystrophy. This is an important finding, since micro-
rupturing of the dystrophic plasmalemma has previously been
implicated in causing disturbed ion fluxes [53]. However, in
contrast to luminal calsequestrin, abnormal expression of the
minor cytosolicCa21-bindingprotein regucalcin [32]was shown
not to be affected by exon skipping. Possibly, certain pathologi-
cal changes due to dystrophin deficiencymay cause irreversible
damage to distinct protein species, regulatory pathways or sig-
nalling mechanism that cannot be rectified using postnatal
therapeutic approaches. In addition to the major restoration of
calsequestrin, the reversal of the upregulation of the small heat
shock protein cvHsp is another indication that exon skipping is
a promising new avenue for the treatment of genetic muscle
diseases. The upregulation of chaperones such as cvHsp can be
considered an autoprotectivemechanismof dystrophic fibres in
response to large numbers of abnormally folded muscle pro-
teins [42].
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Table 1. List of DIGE-identified proteins that exhibit a change of expression in normal versus dystrophic MDX versus exon skipping-treated
MDX-PMO diaphragm muscle
Spot
no.
Name of
identified
proteins
Sequence
coverage
(%)
Molecular
mass (kDa)
pI Protein
accession
no.
t-test Fold change
normal vs.
MDX
Fold change
MDX vs.
MDX-PMO
Fold change
normal vs.
MDX-PMO
1 Heat shock protein cvHSP 20.0 18.66 5.8 gi)6636001) 0.00029 14.28 21.67 12.67
2 Succinate dehydrogenase 25.0 72.6 6.8 gi)18426858) 0.0085 11.77 12.00 13.53
3 Unknown protein – – 2 2 0.0024 11.70 21.09 11.56
4 Unknown protein – – – – 0.033 11.65 21.09 11.51
5 a-Globin 65.0 6.2 6.8 gi)193761) 0.045 11.61 11.61 12.59
6 Aldehyde dehydrogenase 17.7 57.0 7.7 gi)13529509) 0.0021 21.18 11.53 11.29
7 Myosin light chain 55.5 22.5 5.0 gi)33563264) 0.093 21.22 21.36 21.67
8 Creatine kinase,
mitochondrial
30.1 47.9 9.1 gi)38259206) 0.0089 21.36 11.20 21.13
9 Myotilin 10.0 55.5 9.2 gi)34879286) 0.0044 21.54 11.03 21.50
10 Betaine-homocysteine
methyltransferase
19.7 45.5 8.4 gi)62533211) 0.008 21.55 11.16 21.33
11 Unknown protein – – – – 0.0018 21.61 21.17 21.38
12 Myoglobin 20.6 17.2 7.8 gi)11024650) 0.048 21.61 11.35 21.19
13 Triosephosphate
isomerase
60.0 27.4 6.5 gi)12621074) 0.048 21.65 11.38 21.20
14 Isocitrate dehydrogenase 22.0 54.3 9.2 gi)37748684) 0.00074 21.70 11.05 21.62
15 Unknown protein – – – – 0.019 21.79 21.05 21.89
16 Adenylate kinase AK1 31.9 23.3 5.7 gi)10946936) 0.0039 21.84 11.62 12.97
17 Carbonic anhydrase CA3 20.3 29.6 6.9 gi)13786200) 0.027 21.86 21.01 21.87
18 Aldolase 23.5 39.8 8.9 gi)42490830) 0.0045 21.91 11.16 21.65
19 Unknown protein – – – – 0.0015 23.04 11.37 22.22
20 Unknown protein – – – – 0.012 23.31 11.16 22.68
The table shows identification, theoretical molecular mass, theoretical pI, percent sequence coverage, fold-change in expression
and t-test scores for each of the 20 differentially expressed muscle protein in normal versus dystrophic versus treated muscle
fibres.
Table 2. List of DIGE-identified proteins that exhibit a change of expression in dystrophic MDX versus exon skipping-treated MDX-PMO
diaphragm muscle
Spot
no.
Name of identified proteins Sequence
coverage (%)
Molecular
mass (kDa)
pI Protein
accession no.
t-test Fold change MDX
vs. MDX-PMO
1 Unknown protein – – – – 0.00021 12.65
2 b-Haemoglobin 54.8 15.8 7.3 gi)229301) 0.0032 12.17
3 Desmin 26.2 53.5 5.2 gi)33563250) 0.00021 12.15
4 Chaperonin Hsp1 22.9 61.1 5.7 gi)31981679) 0.00024 12.12
5 Vimentin 28.7 51.6 4.9 gi)2078001) 0.00037 11.95
6 Adenylate kinase AK1 31.9 23.3 5.7 gi)10946936) 0.00064 11.86
7 aB Crystallin 28.0 20.1 6.8 gi)14789702) 0.059 11.72
8 Aldolase 27.5 39.8 8.9 gi)42490830) 0.0013 11.65
9 Creatine kinase,mitochondrial 30.1 47.9 9.1 gi)38259206) 4.4e2005 11.65
10 Sorbitol dehydrogenase 25.0 40.6 6.6 gi)25108890) 0.017 11.53
11 Creatine kinase 18.9 43.2 6.6 gi)6671762) 0.0065 11.50
12 Isocitrate dehydrogenase 15.0 54.3 9.2 gi)37748684) 0.0035 11.31
13 Unknown protein – – – – 0.00021 21.14
14 Heat shock protein cvHSP 21.0 18.66 5.8 gi)6636001) 0.00037 21.92
15 Regucalcin 41.0 33.9 5.2 gi)6677739) 4.1e2005 22.45
The table shows identification, theoretical molecular mass, theoretical pI, percent sequence coverage, fold-change in expression and t-test
scores for each of the 15 differentially expressed muscle proteins in dystrophic versus treated muscle fibres.
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In conclusion, this study has clearly demonstrated that
the re-establishment of dystrophin coded by the transcript
missing exon 23 diminishes down-stream pathophysiologi-
cal effects on Ca21-handling, nucleotide metabolism, bio-
energetic pathways and cellular stress response. This estab-
lishes exon skipping as a suitable therapeutic option for rec-
tifying diverse downstream alterations in dystrophinopathy.
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